Apollomics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
APLM Nasdaq 2830 www.apollomicsinc.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Apollomics, Inc.

Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia - Dec 20th, 2024 1:00 pm
Apollomics Regains Compliance with Nasdaq’s Minimum Bid Price Requirement - Dec 10th, 2024 9:05 pm
Apollomics’ Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split - Nov 21st, 2024 1:00 pm
Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at European Society for Medical Oncology (ESMO) Congress 2024 - Sep 16th, 2024 12:00 pm
Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Sep 4th, 2024 8:05 pm
Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress - Aug 14th, 2024 10:00 am
Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial - Aug 13th, 2024 12:00 pm
Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference - Aug 8th, 2024 8:05 pm
Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement - Jul 16th, 2024 8:47 pm
Apollomics Announces Updated Strategic Focus and Leadership Team Changes - Jul 3rd, 2024 12:00 pm
Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - Jun 4th, 2024 12:00 pm
Apollomics Announces Presentation at the 2024 BIO International Convention - May 29th, 2024 12:00 pm
Apollomics Announces Private Placement Financing and Addition to Board of Directors - May 8th, 2024 8:05 pm
Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene - Apr 25th, 2024 12:30 pm
Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting - Apr 10th, 2024 11:00 am
Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting - Apr 2nd, 2024 12:00 pm
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results - Mar 28th, 2024 11:00 am
Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024 - Mar 26th, 2024 12:00 pm
Apollomics Names Matthew Plunkett as Chief Financial Officer - Mar 4th, 2024 3:18 pm
Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer - Mar 4th, 2024 12:00 pm